OIL 3.03% 16.0¢ optiscan imaging limited

Supervet, page-7

  1. 2,505 Posts.
    lightbulb Created with Sketch. 10
    These are the comments in the Annual report re the research instrument and come after the a review of the company by the current management after it took over from May this year. The pre-clinical business has been revamped as part of that process so maybe it would be a good idea to wait and see what the outcome is, you won`t have long to wait as the launch or maybe re-launch will happen in 2016, probably this month at or before the AGM (my guess). Stay calm everyone.


    Near Term Strategy – 2016/17

    The Company has identified three key pillars to its current business model:


    Sales of the second-generation pre-clinical research product This will include:

    Securing sales from the existing customer base of the predecessor model;


    Pursuing established distribution channels; and

    Developing new distribution channels including direct sales and the appointment of new distributors.

    To ensure results will be achieved, the Company announced the appointment of a General Manager - Pre-clinical Research Products to provide dedicated focus in this area.

    The second generation pre-clinical research product has been improved and is planned to be launched in 2016.

    This product will deliver a significant improvement to the existing technology offering in the research market. It is expected that the new product range will secure a significant share of the global market after launch.
 
watchlist Created with Sketch. Add OIL (ASX) to my watchlist
(20min delay)
Last
16.0¢
Change
-0.005(3.03%)
Mkt cap ! $129.4M
Open High Low Value Volume
16.5¢ 16.5¢ 16.0¢ $463 2.89K

Buyers (Bids)

No. Vol. Price($)
1 46748 16.0¢
 

Sellers (Offers)

Price($) Vol. No.
16.5¢ 46940 2
View Market Depth
Last trade - 12.18pm 02/12/2024 (20 minute delay) ?
OIL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.